Literature DB >> 19822052

Challenges comparing functional limitations in rheumatoid arthritis and ankylosing spondylitis.

G H Louie1, J D Reveille, M M Ward.   

Abstract

Whether physical functioning in patients with rheumatoid arthritis (RA) differs from that in patients with ankylosing spondylitis (AS) is presently uncertain. Such a comparison poses challenges, not only because the two diseases differ in the domains of functioning affected, but also because of the different instruments used to measure functional limitations. Limiting our analysis to studies using similar self-report questionnaires, we examined published observational studies of unselected cohorts of patients with RA and patients with AS to compare and contrast the severity of functional limitations. Available studies from a few direct comparisons, and mostly indirect comparisons, suggested that patients with RA are generally more severely limited in physical functioning throughout the disease course than patients with AS. Since most studies did not adjust adequately for potentially important confounders, such as age, gender, comorbidity, and disease duration, reported differences in functional disability between patients with RA and patients with AS must be interpreted cautiously.

Entities:  

Mesh:

Year:  2009        PMID: 19822052      PMCID: PMC2953760     

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  105 in total

1.  Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components.

Authors:  Daniel Aletaha; Josef Smolen; Michael M Ward
Journal:  Arthritis Rheum       Date:  2006-09

2.  Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis.

Authors:  Angela Zink; Katja Thiele; Doerte Huscher; Joachim Listing; Joachim Sieper; Andreas Krause; Erika Gromnica-Ihle; Ulrich von Hinueber; Siegfried Wassenberg; Ekkehard Genth; Matthias Schneider
Journal:  J Rheumatol       Date:  2006-01       Impact factor: 4.666

3.  The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes.

Authors:  Frederick Wolfe; Kaleb Michaud; Theodore Pincus; Daniel Furst; Edward Keystone
Journal:  Arthritis Rheum       Date:  2005-12

4.  Severity of rheumatoid arthritis: the SEVERA study.

Authors:  Rafic Baddoura; Souha Haddad; Hassane Awada; Abdel Fattah Al-Masri; Georges Merheb; Said Attoui; Jad Okais; Jamil Messayke; Fadi Ghandour
Journal:  Clin Rheumatol       Date:  2005-12-15       Impact factor: 2.980

5.  Rheumatology care: Involvement in medical decisions, received information, satisfaction with care, and unmet health care needs in patients with rheumatoid arthritis and ankylosing spondylitis.

Authors:  Ingvild Kjeken; Hanne Dagfinrud; Petter Mowinckel; Till Uhlig; Tore K Kvien; Arnstein Finset
Journal:  Arthritis Rheum       Date:  2006-06-15

6.  Poor and good health outcomes in rheumatoid arthritis: the role of comorbidity.

Authors:  Ines Rupp; Hendriek C Boshuizen; Leo D Roorda; Huibert J Dinant; Catharina E Jacobi; Geertrudis van den Bos
Journal:  J Rheumatol       Date:  2006-08       Impact factor: 4.666

7.  Disability and health-related quality of life among patients with rheumatoid arthritis: association with radiographic joint damage, disease activity, pain, and depressive symptoms.

Authors:  I Rupp; H C Boshuizen; H J Dinant; C E Jacobi; G A M van den Bos
Journal:  Scand J Rheumatol       Date:  2006 May-Jun       Impact factor: 3.641

8.  The reliability, validity and sensitivity to change of the Chinese version of SF-36 in oriental patients with rheumatoid arthritis.

Authors:  E T Koh; K P Leong; I Y Y Tsou; V H Lim; L Y Pong; S Y Chong; A Seow
Journal:  Rheumatology (Oxford)       Date:  2006-02-22       Impact factor: 7.580

9.  Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany.

Authors:  D Huscher; S Merkesdal; K Thiele; H Zeidler; M Schneider; A Zink
Journal:  Ann Rheum Dis       Date:  2006-03-15       Impact factor: 19.103

10.  Costs and quality of life of patients with ankylosing spondylitis in Canada.

Authors:  Gisela Kobelt; Patrik Andlin-Sobocki; Walter P Maksymowych
Journal:  J Rheumatol       Date:  2006-02       Impact factor: 4.666

View more
  6 in total

Review 1.  Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations.

Authors:  Ann M Taylor; Kristine Phillips; Kushang V Patel; Dennis C Turk; Robert H Dworkin; Dorcas Beaton; Daniel J Clauw; Monique A M Gignac; John D Markman; David A Williams; Shay Bujanover; Laurie B Burke; Daniel B Carr; Ernest H Choy; Philip G Conaghan; Penney Cowan; John T Farrar; Roy Freeman; Jennifer Gewandter; Ian Gilron; Veeraindar Goli; Tony D Gover; J David Haddox; Robert D Kerns; Ernest A Kopecky; David A Lee; Richard Malamut; Philip Mease; Bob A Rappaport; Lee S Simon; Jasvinder A Singh; Shannon M Smith; Vibeke Strand; Peter Tugwell; Gertrude F Vanhove; Christin Veasley; Gary A Walco; Ajay D Wasan; James Witter
Journal:  Pain       Date:  2016-09       Impact factor: 7.926

2.  A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis.

Authors:  Brigitte Michelsen; Ragnhild Fiane; Andreas P Diamantopoulos; Dag Magnar Soldal; Inger Johanne W Hansen; Tuulikki Sokka; Arthur Kavanaugh; Glenn Haugeberg
Journal:  PLoS One       Date:  2015-04-08       Impact factor: 3.240

3.  Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.

Authors:  Josef S Smolen; Jürgen Braun; Maxime Dougados; Paul Emery; Oliver Fitzgerald; Philip Helliwell; Arthur Kavanaugh; Tore K Kvien; Robert Landewé; Thomas Luger; Philip Mease; Ignazio Olivieri; John Reveille; Christopher Ritchlin; Martin Rudwaleit; Monika Schoels; Joachim Sieper; Martinus de Wit; Xenofon Baraliakos; Neil Betteridge; Ruben Burgos-Vargas; Eduardo Collantes-Estevez; Atul Deodhar; Dirk Elewaut; Laure Gossec; Merryn Jongkees; Mara Maccarone; Kurt Redlich; Filip van den Bosch; James Cheng-Chung Wei; Kevin Winthrop; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2013-06-08       Impact factor: 19.103

4.  Cost-of-illness and quality of life in patients with ankylosing spondylitis at a tertiary hospital in Korea.

Authors:  Tae-Jin Lee; Bo-Hyun Park; Joon Wan Kim; Kichul Shin; Eun Bong Lee; Yeong-Wook Song
Journal:  J Korean Med Sci       Date:  2014-01-28       Impact factor: 2.153

5.  Development and evaluation of a crosswalk between the SF-36 physical functioning scale and Health Assessment Questionnaire disability index in rheumatoid arthritis.

Authors:  Peter M ten Klooster; Martijn A H Oude Voshaar; Barbara Gandek; Matthias Rose; Jakob B Bjorner; Erik Taal; Cees A W Glas; Piet L C M van Riel; Mart A F J van de Laar
Journal:  Health Qual Life Outcomes       Date:  2013-11-15       Impact factor: 3.186

Review 6.  Biomarkers predicting a need for intensive treatment in patients with early arthritis.

Authors:  I González-Álvaro; A M Ortiz; I V Seoane; R García-Vicuña; C Martínez; R P Gomariz
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.